Tag:
EntreMed
Latest Headlines
Latest Headlines
EntreMed lands $10M deal to fund cancer drug trials
EntreMed ( $ENMD ) has struck a deal to bring in much-needed capital to support development of its experimental kinase inhibitor for attacking multiple types of cancer. And the Rockville, MD-based drug
EntreMed shares spike on PhII cancer data
Shares of EntreMed ( $ENMD ) shot up 18% this morning after the developer posted final data on its primary endpoint for the ovarian cancer drug ENMD-2076. Investigators reported that 22% of the 64
Execs leave EntreMed as it cuts jobs, refocuses
Like so many other small drug developers , Maryland-based EntreMed announced today that it will cut 60 percent of its workforce and focus all its development activities on its lead drug program.
C&L: Gallagher tapped for top Metastatix post
Carol Gallagher, formerly with Anadys Pharmaceuticals, has been named CEO of Metastatix. Pipex Pharmaceuticals has appointed David A. Newsome, M.D. as chief scientific officer. Thomas, McNerney
ALSO NOTED: FDA approves MedPointe's SOMA; EntreMed secures $20M loan; and much more...
> The FDA has approved MedPointe's SOMA (carisoprodol) 250 mg as a new recommended dose for the relief of discomfort associated with acute, painful musculoskeletal conditions, such as backache.
